Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AKCEA THERAPEUTICS, INC.AKCA · Entity 145982 | Director · President | July 15, 2019 | July 17, 2019 |
| Atrium Therapeutics, Inc.RNA · Entity 6185 | Director | September 18, 2026 | September 22, 2026 |
| Bruker Cellular Analysis, Inc.BLI · Entity 109250 | Director | May 14, 2021 | May 18, 2021 |
| Contineum Therapeutics, Inc.CTNM · Entity 5311 | Director | June 26, 2026 | June 26, 2026 |
| IONIS PHARMACEUTICALS INCIONS · Entity 1182 | Chief Business Officer | January 15, 2018 | January 18, 2018 |
| OmniAb, Inc.OABI · Entity 5294 | Director | June 18, 2024 | June 21, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AKCEA THERAPEUTICS, INC.
Report date July 15, 2019 · Filed July 17, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 19,888 |
Reported balance
After 2019-07-15 transaction · row 1
1 source rowRow 1 · 2019-07-15 · Sale · Disposed 1,819 · Balance 19,888 F1: Sale of shares of common stock to cover tax withholding obligations associated with the vesting of a Restricted Stock Unit Award granted to the Reporting Person on April 17, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: Sale of shares of common stock to cover tax withholding obligations associated with the vesting of a Restricted Stock Unit Award granted to the Reporting Person on April 17, 2018.
Atrium Therapeutics, Inc.
Report date September 18, 2026 · Filed September 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 138,668 |
Reported balance
After 2026-09-18 transaction · row 1
1 source rowRow 1 · 2026-09-18 · Tax withholding · Disposed 126,418 · Balance 138,668 F1: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units.
Bruker Cellular Analysis, Inc.
Report date May 14, 2021 · Filed May 18, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,400 |
Reported balance
After 2021-05-14 transaction · row 1
1 source rowRow 1 · 2021-05-14 · Grant · Acquired 1,400 · Balance 1,400 F1: Represents an award of restricted stock units ('RSUs'). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on May 14, 2022 and have no expiration date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.13 · Expires 2031-05-13 | Direct | 4,900 |
Reported balance
After 2021-05-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-05-14 · Grant · Acquired 4,900 · Balance 4,900 F2: The stock option will fully vest on May 14, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an award of restricted stock units ('RSUs'). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on May 14, 2022 and have no expiration date.
F2: The stock option will fully vest on May 14, 2022.
Contineum Therapeutics, Inc.
Report date June 26, 2026 · Filed June 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.19 · Expires 2036-06-25 | Direct | 19,000 |
Reported balance
After 2026-06-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-26 · Grant · Acquired 19,000 · Balance 19,000 F1: Options granted under the Issuer's 2024 Equity Incentive Plan (the "Plan"), pursuant to the Issuer's Non-Employee Director Compensation Program, as amended, which states that upon the conclusion of each regular annual meeting of the Company's stockholders, each non-employee director who continues to serve as a member of the Company's Board of Directors thereafter will automatically be granted a stock option under the Plan for 19,000 shares of the Company's Class A Common Stock. Option will vest in full on the earlier of (i) June 26, 2027, the one-year anniversary of the date of grant, or (ii) the next regular annual meeting of stockholders, subject to the Reporting Person's continuous service. |
Filing footnotes · ownership attribution and instrument terms
F1: Options granted under the Issuer's 2024 Equity Incentive Plan (the "Plan"), pursuant to the Issuer's Non-Employee Director Compensation Program, as amended, which states that upon the conclusion of each regular annual meeting of the Company's stockholders, each non-employee director who continues to serve as a member of the Company's Board of Directors thereafter will automatically be granted a stock option under the Plan for 19,000 shares of the Company's Class A Common Stock. Option will vest in full on the earlier of (i) June 26, 2027, the one-year anniversary of the date of grant, or (ii) the next regular annual meeting of stockholders, subject to the Reporting Person's continuous service.
IONIS PHARMACEUTICALS INC
Report date January 15, 2018 · Filed January 18, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,931 |
Ending reported balance
After 2018-01-16 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2018-01-15 · Exercise / conversion · Acquired 5,367 · Balance 11,127 F1: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. Row 2 · 2018-01-16 · Sale · Disposed 2,196 · Balance 8,931 F2: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 12,916 |
Reported balance
After 2018-01-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-01-15 · Grant · Acquired 12,916 · Balance 12,916 F3: Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. F5: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F4: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 10,427 |
Reported balance
After 2018-01-15 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-01-15 · Exercise / conversion · Disposed 5,367 · Balance 10,427 F5: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F4: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards.
F2: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.
F3: Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan.
F4: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.
F5: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.
OmniAb, Inc.
Report date June 18, 2024 · Filed June 21, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 68,381 |
Reported balance
After 2024-06-18 transaction · row 1
1 source rowRow 1 · 2024-06-18 · Exercise / conversion · Acquired 20,000 · Balance 68,381 F1: Represents the vesting of an RSU granted on June 23, 2023, which occurs on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the grant date. F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-06-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-06-18 · Exercise / conversion · Disposed 20,000 · Balance 0 F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F1: Represents the vesting of an RSU granted on June 23, 2023, which occurs on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the grant date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 20,000 |
Reported balance
After 2024-06-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-06-18 · Grant · Acquired 20,000 · Balance 20,000 F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3: The RSUs shall vest in full on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the grant date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.19 · Expires 2034-06-18 | Direct | 40,000 |
Reported balance
After 2024-06-18 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-06-18 · Grant · Acquired 40,000 · Balance 40,000 F4: Each Stock Option shall vest and become exercisable in full on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the vesting of an RSU granted on June 23, 2023, which occurs on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the grant date.
F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F3: The RSUs shall vest in full on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the grant date.
F4: Each Stock Option shall vest and become exercisable in full on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the grant date.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Avidity Biosciences, Inc.
Report date February 27, 2026 · Filed February 27, 2026
Section 16 reporting ended · disclosed 2026-02-27. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 1
1 source rowRow 1 · 2026-02-27 · Disposition to issuer · Disposed 474,861 · Balance 0 F1: The reported securities represent shares of Common Stock (inclusive of shares of Common Stock issuable upon settlement of previously reported restricted stock units) disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of October 25, 2025 (the "Merger Agreement"), among Novartis AG ("Novartis"), Ajax Acquisition Sub, Inc., an indirect wholly owned subsidiary of Novartis, and the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.24 · Expires 2029-12-17 | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-27 · Disposition to issuer · Disposed 386,015 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.34 · Expires 2031-02-01 | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-27 · Disposition to issuer · Disposed 300,000 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.22 · Expires 2032-01-20 | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-02-27 · Disposition to issuer · Disposed 425,000 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.47 · Expires 2033-01-19 | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-02-27 · Disposition to issuer · Disposed 400,000 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.57 · Expires 2033-09-10 | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-02-27 · Disposition to issuer · Disposed 200,000 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.16 · Expires 2034-01-19 | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-02-27 · Disposition to issuer · Disposed 300,000 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.42 · Expires 2035-01-05 | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-02-27 · Disposition to issuer · Disposed 165,000 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities represent shares of Common Stock (inclusive of shares of Common Stock issuable upon settlement of previously reported restricted stock units) disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of October 25, 2025 (the "Merger Agreement"), among Novartis AG ("Novartis"), Ajax Acquisition Sub, Inc., an indirect wholly owned subsidiary of Novartis, and the Issuer.
F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price.
LIGAND PHARMACEUTICALS INC
Report date November 01, 2022 · Filed November 04, 2022
Section 16 reporting ended · disclosed 2022-11-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,892 |
Reported balance
After 2022-11-01 transaction · row 1
1 source rowRow 1 · 2022-11-01 · Disposition to issuer · Disposed 1,004 · Balance 2,892 F1: Certain of the Reporting Person's equity awards were cancelled in connection with the separation of OmniAb, Inc. from the Issuer on November 1, 2022. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $90.68 · Expires 2032-06-10 | Direct | 0 |
Reported balance
After 2022-11-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-11-01 · Disposition to issuer · Disposed 4,340 · Balance 0 F1: Certain of the Reporting Person's equity awards were cancelled in connection with the separation of OmniAb, Inc. from the Issuer on November 1, 2022. F2: The stock option vests and is exercisable on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders following the grant date or (ii) on June 10, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: Certain of the Reporting Person's equity awards were cancelled in connection with the separation of OmniAb, Inc. from the Issuer on November 1, 2022.
F2: The stock option vests and is exercisable on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders following the grant date or (ii) on June 10, 2023.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 13, 2024 Filed Jun 14, 2024 22:58 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionStock Option (Right to Buy) · Derivative | 164,233 | $0.00 Strike: $1.24 | $0.00 |
DisclosureSEC source: 0001599901-24-000093 · wk-form4_1718405894.xml · derivative · entry 8 Boyce Sarah · CIK 0001629383 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 552,782 Underlying: Common Stock · 164,233 shares Expires 2029-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted on June 9, 2023 by the Reporting Person. F5 · derivative.exercise_date: All unexercised shares subject to the option are fully vested and exercisable as of the date hereof. Read SEC document |
| June 13, 2024 Filed Jun 14, 2024 22:58 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 164,233 | $40.08 | $6,581,801.71 |
DisclosureSEC source: 0001599901-24-000093 · wk-form4_1718405894.xml · nonDerivative · entry 4 Boyce Sarah · CIK 0001629383 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 112,117 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted on June 9, 2023 by the Reporting Person. F3 · price: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.35. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 13, 2024 Filed Jun 14, 2024 22:58 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionCommon Stock | 164,233 | $1.24 | $203,648.92 |
DisclosureSEC source: 0001599901-24-000093 · wk-form4_1718405894.xml · nonDerivative · entry 3 Boyce Sarah · CIK 0001629383 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 276,350 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted on June 9, 2023 by the Reporting Person. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 22:58 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $1.24 | $0.00 |
DisclosureSEC source: 0001599901-24-000093 · wk-form4_1718405894.xml · derivative · entry 7 Boyce Sarah · CIK 0001629383 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 717,015 Underlying: Common Stock · 100,000 shares Expires 2029-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted on June 9, 2023 by the Reporting Person. F5 · derivative.exercise_date: All unexercised shares subject to the option are fully vested and exercisable as of the date hereof. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 22:58 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 100,000 | $35.73 | $3,573,020.00 |
DisclosureSEC source: 0001599901-24-000093 · wk-form4_1718405894.xml · nonDerivative · entry 2 Boyce Sarah · CIK 0001629383 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 112,117 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted on June 9, 2023 by the Reporting Person. F2 · price: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $37.57. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 22:58 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionCommon Stock | 100,000 | $1.24 | $124,000.00 |
DisclosureSEC source: 0001599901-24-000093 · wk-form4_1718405894.xml · nonDerivative · entry 1 Boyce Sarah · CIK 0001629383 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 212,117 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted on June 9, 2023 by the Reporting Person. Read SEC document |
| June 04, 2024 Filed Jun 5, 2024 21:46 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionStock Option (Right to Buy) · Derivative | 28,000 | $0.00 Strike: $1.24 | $0.00 |
DisclosureSEC source: 0001599901-24-000077 · wk-form4_1717623967.xml · derivative · entry 3 Boyce Sarah · CIK 0001629383 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 817,015 Underlying: Common Stock · 28,000 shares Expires 2029-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted on June 9, 2023 by the Reporting Person. F3 · derivative.exercise_date: All unexercised shares subject to the option are fully vested and exercisable as of the date hereof. Read SEC document |
| June 04, 2024 Filed Jun 5, 2024 21:46 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 28,000 | $27.42 | $767,779.60 |
DisclosureSEC source: 0001599901-24-000077 · wk-form4_1717623967.xml · nonDerivative · entry 2 Boyce Sarah · CIK 0001629383 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 112,117 F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted on June 9, 2023 by the Reporting Person. F2 · price: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $26.30 to $27.87. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 04, 2024 Filed Jun 5, 2024 21:46 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionCommon Stock | 28,000 | $1.24 | $34,720.00 |
DisclosureSEC source: 0001599901-24-000077 · wk-form4_1717623967.xml · nonDerivative · entry 1 Boyce Sarah · CIK 0001629383 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 140,117 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted on June 9, 2023 by the Reporting Person. Read SEC document |
| May 07, 2024 Filed May 8, 2024 01:52 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionStock Option (Right to Buy) · Derivative | 28,000 | $0.00 Strike: $1.24 | $0.00 |
DisclosureSEC source: 0001599901-24-000064 · wk-form4_1715133165.xml · derivative · entry 3 Boyce Sarah · CIK 0001629383 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 845,015 Underlying: Common Stock · 28,000 shares Expires 2029-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F4 · derivative.exercise_date: All unexercised shares subject to the option are fully vested and exercisable as of the date hereof. Read SEC document |
| May 07, 2024 Filed May 8, 2024 01:52 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 28,000 | $25.54 | $715,050.00 |
DisclosureSEC source: 0001599901-24-000064 · wk-form4_1715133165.xml · nonDerivative · entry 2 Boyce Sarah · CIK 0001629383 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 112,117 F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F3 · price: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $25.01 to $26.56. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes the following securities previously acquired by the Reporting Person: (i) 107,408 restricted stock units under the Issuer's 2020 Incentive Award Plan and (ii) 4,709 shares of common stock under the Issuer's 2020 Employee Stock Purchase Plan. Read SEC document |
| May 07, 2024 Filed May 8, 2024 01:52 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionCommon Stock | 28,000 | $1.24 | $34,720.00 |
DisclosureSEC source: 0001599901-24-000064 · wk-form4_1715133165.xml · nonDerivative · entry 1 Boyce Sarah · CIK 0001629383 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 140,117 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · balance_after: Includes the following securities previously acquired by the Reporting Person: (i) 107,408 restricted stock units under the Issuer's 2020 Incentive Award Plan and (ii) 4,709 shares of common stock under the Issuer's 2020 Employee Stock Purchase Plan. Read SEC document |
| April 02, 2024 Filed Apr 3, 2024 22:16 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionStock Option (Right to Buy) · Derivative | 28,000 | $0.00 Strike: $1.24 | $0.00 |
DisclosureSEC source: 0001599901-24-000049 · wk-form4_1712182590.xml · derivative · entry 3 Boyce Sarah · CIK 0001629383 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 873,015 Underlying: Common Stock · 28,000 shares Expires 2029-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: All unexercised shares subject to the option are fully vested and exercisable as of the date hereof. Read SEC document |
| April 02, 2024 Filed Apr 3, 2024 22:16 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 28,000 | $26.25 | $734,918.80 |
DisclosureSEC source: 0001599901-24-000049 · wk-form4_1712182590.xml · nonDerivative · entry 2 Boyce Sarah · CIK 0001629383 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 112,117 F2 · price: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $25.10 to $26.97. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · balance_after: Includes the following securities previously acquired by the Reporting Person: (i) 107,408 restricted stock units under the Issuer's 2020 Incentive Award Plan and (ii) 4,709 shares of common stock under the Issuer's 2020 Employee Stock Purchase Plan. Read SEC document |
| April 02, 2024 Filed Apr 3, 2024 22:16 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionCommon Stock | 28,000 | $1.24 | $34,720.00 |
DisclosureSEC source: 0001599901-24-000049 · wk-form4_1712182590.xml · nonDerivative · entry 1 Boyce Sarah · CIK 0001629383 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 140,117 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes the following securities previously acquired by the Reporting Person: (i) 107,408 restricted stock units under the Issuer's 2020 Incentive Award Plan and (ii) 4,709 shares of common stock under the Issuer's 2020 Employee Stock Purchase Plan. Read SEC document |
| March 12, 2024 Filed Mar 12, 2024 21:29 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionStock Option (Right to Buy) · Derivative | 28,000 | $0.00 Strike: $1.24 | $0.00 |
DisclosureSEC source: 0001599901-24-000040 · wk-form4_1710278963.xml · derivative · entry 6 Boyce Sarah · CIK 0001629383 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 901,015 Underlying: Common Stock · 28,000 shares Expires 2029-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: All unexercised shares subject to the option are fully vested and exercisable as of the date hereof. Read SEC document |
| March 12, 2024 Filed Mar 12, 2024 21:29 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 28,000 | $22.63 | $633,682.00 |
DisclosureSEC source: 0001599901-24-000040 · wk-form4_1710278963.xml · nonDerivative · entry 4 Boyce Sarah · CIK 0001629383 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 112,117 F3 · price: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $22.61 to $22.71. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · balance_after: Includes the following securities previously acquired by the Reporting Person: (i) 107,408 restricted stock units under the Issuer's 2020 Incentive Award Plan and (ii) 4,709 shares of common stock under the Issuer's 2020 Employee Stock Purchase Plan. Read SEC document |
| March 12, 2024 Filed Mar 12, 2024 21:29 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionCommon Stock | 28,000 | $1.24 | $34,720.00 |
DisclosureSEC source: 0001599901-24-000040 · wk-form4_1710278963.xml · nonDerivative · entry 3 Boyce Sarah · CIK 0001629383 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 140,117 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes the following securities previously acquired by the Reporting Person: (i) 107,408 restricted stock units under the Issuer's 2020 Incentive Award Plan and (ii) 4,709 shares of common stock under the Issuer's 2020 Employee Stock Purchase Plan. Read SEC document |
| March 08, 2024 Filed Mar 12, 2024 21:29 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionStock Option (Right to Buy) · Derivative | 84,000 | $0.00 Strike: $1.24 | $0.00 |
DisclosureSEC source: 0001599901-24-000040 · wk-form4_1710278963.xml · derivative · entry 5 Boyce Sarah · CIK 0001629383 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 929,015 Underlying: Common Stock · 84,000 shares Expires 2029-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: All unexercised shares subject to the option are fully vested and exercisable as of the date hereof. Read SEC document |
| March 08, 2024 Filed Mar 12, 2024 21:29 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 84,000 | $21.39 | $1,796,709.60 |
DisclosureSEC source: 0001599901-24-000040 · wk-form4_1710278963.xml · nonDerivative · entry 2 Boyce Sarah · CIK 0001629383 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 112,117 F2 · price: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $21.33 to $21.54. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · balance_after: Includes the following securities previously acquired by the Reporting Person: (i) 107,408 restricted stock units under the Issuer's 2020 Incentive Award Plan and (ii) 4,709 shares of common stock under the Issuer's 2020 Employee Stock Purchase Plan. Read SEC document |
| March 08, 2024 Filed Mar 12, 2024 21:29 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionCommon Stock | 84,000 | $1.24 | $104,160.00 |
DisclosureSEC source: 0001599901-24-000040 · wk-form4_1710278963.xml · nonDerivative · entry 1 Boyce Sarah · CIK 0001629383 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 196,117 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes the following securities previously acquired by the Reporting Person: (i) 107,408 restricted stock units under the Issuer's 2020 Incentive Award Plan and (ii) 4,709 shares of common stock under the Issuer's 2020 Employee Stock Purchase Plan. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:53 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionStock Option (Right to Buy) · Derivative | 84,000 | $0.00 Strike: $1.24 | $0.00 |
DisclosureSEC source: 0001599901-24-000038 · wk-form4_1709675574.xml · derivative · entry 3 Boyce Sarah · CIK 0001629383 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,013,015 Underlying: Common Stock · 84,000 shares Expires 2029-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: All unexercised shares subject to the option are fully vested exercisable as of the date hereof. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:53 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 84,000 | $20.13 | $1,691,306.40 |
DisclosureSEC source: 0001599901-24-000038 · wk-form4_1709675574.xml · nonDerivative · entry 2 Boyce Sarah · CIK 0001629383 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 112,117 F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $20.12 to $20.23. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · balance_after: Includes the following securities previously acquired by the Reporting Person: (i) 106,508 restricted stock units under the Issuer's 2020 Incentive Award Plan and (ii) 4,709 shares of common stock under the Issuer's 2020 Employee Stock Purchase Plan. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:53 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionCommon Stock | 84,000 | $1.24 | $104,160.00 |
DisclosureSEC source: 0001599901-24-000038 · wk-form4_1709675574.xml · nonDerivative · entry 1 Boyce Sarah · CIK 0001629383 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 196,117 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes the following securities previously acquired by the Reporting Person: (i) 106,508 restricted stock units under the Issuer's 2020 Incentive Award Plan and (ii) 4,709 shares of common stock under the Issuer's 2020 Employee Stock Purchase Plan. Read SEC document |
| January 22, 2024 Filed Jan 23, 2024 20:13 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 5,092 | $10.13 | $51,581.96 |
DisclosureSEC source: 0001599901-24-000011 · wk-form4_1706040821.xml · nonDerivative · entry 2 Boyce Sarah · CIK 0001629383 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,008 F3 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs on January 20, 2024. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary trade by the Reporting Person. The Reporting Person has executed an instruction letter for the automatic sale of such "sell-to-cover" shares, intended to satisfy the affirmative defense conditions of Rule 10b5-1. Read SEC document |
| January 20, 2024 Filed Jan 23, 2024 20:13 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | GrantStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $10.16 | $0.00 |
DisclosureSEC source: 0001599901-24-000011 · wk-form4_1706040821.xml · derivative · entry 3 Boyce Sarah · CIK 0001629383 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2034-01-19 F4 · derivative.exercise_date: 1/48th of the total number of shares subject to the options shall vest on each monthly anniversary of January 20, 2024 (the "Vesting Commencement Date"), subject to the Reporting Person's continuous service to the Issuer on each such vesting date, so that the options shall be fully vested on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| January 20, 2024 Filed Jan 23, 2024 20:13 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | GrantCommon Stock | 62,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001599901-24-000011 · wk-form4_1706040821.xml · nonDerivative · entry 1 Boyce Sarah · CIK 0001629383 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 67,209 F1 · shares: Represents restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in four equal installments on the first four anniversaries of January 20, 2024, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. F2 · balance_after: Includes 4,709 shares previously acquired by the Reporting Person under the Avidity Biosciences, Inc. 2020 Employee Stock Purchase Plan. Read SEC document |
| September 11, 2023 Filed Sep 12, 2023 23:34 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $6.57 | $0.00 |
DisclosureSEC source: 0001599901-23-000072 · wk-form4_1694561653.xml · derivative · entry 1 Boyce Sarah · CIK 0001629383 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2033-09-10 F1 · derivative.exercise_date: 1/48th of the total number of shares subject to the options shall vest on each monthly anniversary of September 11, 2023 (the "Vesting Commencement Date"), subject to the Reporting Person's continuous service to the Issuer on each such vesting date, so that the options shall be fully vested on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| June 23, 2023 Filed Jun 27, 2023 21:44 UTC | OmniAb, Inc. OABI · Entity 5294 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $4.81 | $0.00 |
DisclosureSEC source: 0001846253-23-000084 · primary_doc.xml · derivative · entry 2 Boyce Sarah · CIK 0001629383 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2033-06-23 F2 · derivative.exercise_date: Each Stock Option shall vest and become exercisable in full on the earlier of (A) the date of the annual meeting of the Company's stockholders next following the grant date and (B) on the first anniversary of the date of grant. Read SEC document |
| June 23, 2023 Filed Jun 27, 2023 21:44 UTC | OmniAb, Inc. OABI · Entity 5294 | GrantRestricted Stock Units · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001846253-23-000084 · primary_doc.xml · derivative · entry 1 Boyce Sarah · CIK 0001629383 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest in full on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the date of grant. F1 · derivative.exercise_date: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest in full on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the date of grant. F1 · derivative.expiration_date: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest in full on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the date of grant. Read SEC document |
| February 03, 2023 Filed Feb 3, 2023 22:26 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionStock Option (Right to · Derivative | 3,221 | $0.00 Strike: $1.24 | $0.00 |
DisclosureSEC source: 0001209191-23-007092 · doc4.xml · derivative · entry 9 Boyce Sarah · CIK 0001629383 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,097,015 Underlying: Common Stock · 3,221 shares Expires 2029-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F5 · derivative.exercise_date: 25% of the shares subject to the option vested on October 7, 2020 and 1/48th of the shares subject to the option will vest monthly thereafter. Read SEC document |
| February 03, 2023 Filed Feb 3, 2023 22:26 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 3,221 | $24.26 | $78,141.46 |
DisclosureSEC source: 0001209191-23-007092 · doc4.xml · nonDerivative · entry 6 Boyce Sarah · CIK 0001629383 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,352 F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes restricted stock units. Read SEC document |
| February 03, 2023 Filed Feb 3, 2023 22:26 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionCommon Stock | 3,221 | $1.24 | $3,994.04 |
DisclosureSEC source: 0001209191-23-007092 · doc4.xml · nonDerivative · entry 5 Boyce Sarah · CIK 0001629383 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,573 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes restricted stock units. Read SEC document |
| February 02, 2023 Filed Feb 3, 2023 22:26 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionStock Option (Right to Buy) · Derivative | 45,879 | $0.00 Strike: $1.24 | $0.00 |
DisclosureSEC source: 0001209191-23-007092 · doc4.xml · derivative · entry 8 Boyce Sarah · CIK 0001629383 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,100,236 Underlying: Common Stock · 45,879 shares Expires 2029-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F5 · derivative.exercise_date: 25% of the shares subject to the option vested on October 7, 2020 and 1/48th of the shares subject to the option will vest monthly thereafter. Read SEC document |
| February 02, 2023 Filed Feb 3, 2023 22:26 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 45,879 | $24.36 | $1,117,740.90 |
DisclosureSEC source: 0001209191-23-007092 · doc4.xml · nonDerivative · entry 4 Boyce Sarah · CIK 0001629383 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,352 F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $24.26 to $24.68.The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes restricted stock units. Read SEC document |
| February 02, 2023 Filed Feb 3, 2023 22:26 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionCommon Stock | 45,879 | $1.24 | $56,889.96 |
DisclosureSEC source: 0001209191-23-007092 · doc4.xml · nonDerivative · entry 3 Boyce Sarah · CIK 0001629383 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,231 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes restricted stock units. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 22:26 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionStock Option (Right to Buy) · Derivative | 900 | $0.00 Strike: $1.24 | $0.00 |
DisclosureSEC source: 0001209191-23-007092 · doc4.xml · derivative · entry 7 Boyce Sarah · CIK 0001629383 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,146,115 Underlying: Common Stock · 900 shares Expires 2029-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F5 · derivative.exercise_date: 25% of the shares subject to the option vested on October 7, 2020 and 1/48th of the shares subject to the option will vest monthly thereafter. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 22:26 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 900 | $24.27 | $21,844.44 |
DisclosureSEC source: 0001209191-23-007092 · doc4.xml · nonDerivative · entry 2 Boyce Sarah · CIK 0001629383 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,352 F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $24.26 to $24.31.The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes restricted stock units. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 22:26 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionCommon Stock | 900 | $1.24 | $1,116.00 |
DisclosureSEC source: 0001209191-23-007092 · doc4.xml · nonDerivative · entry 1 Boyce Sarah · CIK 0001629383 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,252 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes restricted stock units. Read SEC document |
| January 30, 2023 Filed Feb 1, 2023 19:10 UTC | OmniAb, Inc. OABI · Entity 5294 | GrantStock Option · Derivative | 37,840 | $0.00 Strike: $4.25 | $0.00 |
DisclosureSEC source: 0001846253-23-000009 · edgardoc.xml · derivative · entry 3 Boyce Sarah · CIK 0001629383 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,840 Underlying: Common Stock · 37,840 shares Expires 2033-01-30 F2 · derivative.exercise_date: The stock option fully vests on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders or (ii) on the first Grant Date Anniversary. Read SEC document |
| January 30, 2023 Filed Feb 1, 2023 19:10 UTC | OmniAb, Inc. OABI · Entity 5294 | GrantCommon Stock | 8,753 | $0.00 | $0.00 |
DisclosureSEC source: 0001846253-23-000009 · edgardoc.xml · nonDerivative · entry 1 Boyce Sarah · CIK 0001629383 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,190 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSU fully vests on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders or (ii) on the first Grant Date Anniversary. Read SEC document |
| January 20, 2023 Filed Jan 25, 2023 02:13 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | GrantStock Option (Right to Buy) · Derivative | 400,000 | $0.00 Strike: $22.47 | $0.00 |
DisclosureSEC source: 0001209191-23-004768 · doc4.xml · derivative · entry 2 Boyce Sarah · CIK 0001629383 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2033-01-19 F3 · derivative.exercise_date: 1/48th of the total number of shares subject to the options shall vest on each monthly anniversary of January 20, 2023 (the "Vesting Commencement Date"), subject to the Reporting Person's continuous service to the Issuer on each such vesting date, so that the options shall be fully vested on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| January 20, 2023 Filed Jan 25, 2023 02:13 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-004768 · doc4.xml · nonDerivative · entry 1 Boyce Sarah · CIK 0001629383 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,352 F1 · shares: Represents restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in four equal installments on the first four anniversaries of January 20, 2023, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. F2 · balance_after: Includes 3,352 shares previously acquired by the Reporting Person under the Avidity Biosciences, Inc. 2020 Employee Stock Purchase Plan. Read SEC document |
| November 10, 2022 Filed Nov 14, 2022 21:30 UTC | OmniAb, Inc. OABI · Entity 5294 | PurchaseCommon Stock | 15,000 | $2.92 | $43,800.00 |
DisclosureSEC source: 0000899243-22-035698 · doc4.xml · nonDerivative · entry 2 Boyce Sarah · CIK 0001629383 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 36,000 Read SEC document |
| November 09, 2022 Filed Nov 14, 2022 21:30 UTC | OmniAb, Inc. OABI · Entity 5294 | PurchaseCommon Stock | 21,000 | $2.74 | $57,596.70 |
DisclosureSEC source: 0000899243-22-035698 · doc4.xml · nonDerivative · entry 1 Boyce Sarah · CIK 0001629383 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 21,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.71 to $2.79. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| November 01, 2022 Filed Nov 4, 2022 01:06 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 4,340 | Not disclosed Strike: $90.68 | Not disclosed |
DisclosureSEC source: 0000899243-22-035036 · doc4.xml · derivative · entry 2 Boyce Sarah · CIK 0001629383 · Former Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,340 shares Expires 2032-06-10 F1 · kind: Certain of the Reporting Person's equity awards were cancelled in connection with the separation of OmniAb, Inc. from the Issuer on November 1, 2022. F1 · price: Certain of the Reporting Person's equity awards were cancelled in connection with the separation of OmniAb, Inc. from the Issuer on November 1, 2022. F2 · derivative.exercise_date: The stock option vests and is exercisable on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders following the grant date or (ii) on June 10, 2023. Read SEC document |
| November 01, 2022 Filed Nov 4, 2022 01:06 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Disposition to issuerCommon Stock | 1,004 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-035036 · doc4.xml · nonDerivative · entry 1 Boyce Sarah · CIK 0001629383 · Former Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,892 F1 · kind: Certain of the Reporting Person's equity awards were cancelled in connection with the separation of OmniAb, Inc. from the Issuer on November 1, 2022. F1 · price: Certain of the Reporting Person's equity awards were cancelled in connection with the separation of OmniAb, Inc. from the Issuer on November 1, 2022. Read SEC document |
| November 01, 2022 Filed Nov 4, 2022 01:15 UTC | OmniAb, Inc. OABI · Entity 5294 | GrantStock Option · Derivative | 37,840 | Not disclosed Strike: $9.10 | Not disclosed |
DisclosureSEC source: 0000899243-22-035062 · doc4.xml · derivative · entry 5 Boyce Sarah · CIK 0001629383 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,840 Underlying: Common Stock · 37,840 shares Expires 2032-06-10 F1 · kind: Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. ("Legacy OmniAb"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement. F1 · price: Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. ("Legacy OmniAb"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement. F5 · derivative.exercise_date: The stock option fully vests on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders or (ii) on June 10, 2023. Read SEC document |
| November 01, 2022 Filed Nov 4, 2022 01:15 UTC | OmniAb, Inc. OABI · Entity 5294 | GrantStock Option · Derivative | 13,994 | Not disclosed Strike: $13.24 | Not disclosed |
DisclosureSEC source: 0000899243-22-035062 · doc4.xml · derivative · entry 4 Boyce Sarah · CIK 0001629383 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,994 Underlying: Common Stock · 13,994 shares Expires 2031-06-04 F1 · kind: Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. ("Legacy OmniAb"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement. F1 · price: Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. ("Legacy OmniAb"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement. F4 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| November 01, 2022 Filed Nov 4, 2022 01:15 UTC | OmniAb, Inc. OABI · Entity 5294 | GrantStock Option · Derivative | 10,565 | Not disclosed Strike: $13.49 | Not disclosed |
DisclosureSEC source: 0000899243-22-035062 · doc4.xml · derivative · entry 3 Boyce Sarah · CIK 0001629383 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,565 Underlying: Common Stock · 10,565 shares Expires 2030-06-10 F1 · kind: Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. ("Legacy OmniAb"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement. F1 · price: Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. ("Legacy OmniAb"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement. F4 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.